Vital Signs Monitoring Central - ANVISA Registration 80624030000
Access comprehensive regulatory information for Vital Signs Monitoring Central in Brazil's medical device market through Pure Global AI's free database. This Risk Class III medical device is registered under ANVISA number 80624030000 and manufactured by manufacturer not specified. The registration is held by SAFE SUPORTE A VIDA E COMERCIO INTERNACIONAL LTDA with validity until Jun 12, 2027.
This page provides complete technical specifications for 2 related devices, regulatory compliance details, 5 companies making the same product including PHILIPS MEDIZIN SYSTEME BOBLINGEN GMBH, LIFEMED INDUSTRIAL DE EQUIPAMENTOS E ARTiGOS MรDICOS E HOSPITALARES S.A, and 5 recent registrations in the same technical category. Pure Global AI offers free access to over 100,000+ Brazilian medical device registrations, helping global MedTech companies navigate ANVISA regulations, identify competitors, and discover partnership opportunities efficiently.
Related Devices (2)
Registration Details
80624030000
25351469687202188
08675394000190
Company Information
Dates and Status
Jun 14, 2021
12/06/2027
09/18/2025 19:00:01
PHILIPS MEDIZIN SYSTEME BOBLINGEN GMBHโข Germany
LIFEMED INDUSTRIAL DE EQUIPAMENTOS E ARTiGOS MรDICOS E HOSPITALARES S.Aโข Brazil
SHENZHEN CREATIVE INDUSTRY CO., LTD.โข China
SIEMENS HEALTHCARE GMBHโข Germany
DRรGER MEDICAL SYSTEMS, INC.โข United States of America
Central de Monitorizacao de Sinais Vitais
CENTRAL DE MONITORAMENTO HEMEROS
ALFA MED SISTEMAS MEDICOS LTDA
80629370022
Feb 24, 2025
Central de Monitorizacao de Sinais Vitais
Vista CMS
Not specified
10303940034
Dec 02, 2024
Central de Monitorizacao de Sinais Vitais
Vista CMS
SHANGHAI DRรGER MEDICAL INSTRUMENT CO., LTD.
10303940034
Dec 02, 2024
Central de Monitorizacao de Sinais Vitais
SISTEMA CENTRAL DE MONITORAMENTO - BIOVISION
GUANGDONG BIOLIGHT MEDITECH CO., LTD
81838410012
Aug 26, 2024
Central de Monitorizacao de Sinais Vitais
SISTEMA CENTRAL DE MONITORAMENTO - BIOVISION
Not specified
81838410012
Aug 26, 2024

